Skip to main content

BIOADAPTIVES, INC.

For the period ended Dec 31, 2025. Filed Apr 14, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Apr 14, 2026

BDPTStored price and day change unavailable
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-K** **

(Mark one)

**For the fiscal year ended December 31, 2025 **

☐Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934

For the transition period from ______________ to _____________

Commission File Number:000-54949

BioAdaptives, Inc.

(Exact name of registrant as specified in its charter)

Delaware46-2592228
(State of incorporation)(IRS Employer ID Number)

2620 Regatta Drive, Suite 102, Las Vegas, NV

(Address of principal executive offices)

(702)659-8829

(Issuer's telephone number)

__________________________________________________________________________________________

Securities registered pursuant to Section 12 (b) of the Act - None

Securities registered pursuant to Section 12(g) of the Act: - Common Stock - $0.0001 par value

__________________________________________________________________________________________

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐No ☒

Indicate by check mark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the

Exchange Act during the past 12 months (or for such shorter period the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post files). Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☒

**Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):**Yes☐ No ☒

The aggregate market value of voting and non-voting common equity held by non-affiliates as of December 31, 2025 was approximately $252,181.80 based upon 12,008,659 shares issued and outstanding.

As of December 31, 2025, there were 12,008,65 shares of Common Stock issued and outstanding. As of March 24, 2025, we had 12,008,659 shares of our Common Stock issued and outstanding.

BioAdaptives, Inc.

Form 10-K for the Year Ended December 31, 2025

BioAdaptives, Inc.

Form 10-K for the Year Ended December 31, 2025

Index to Contents

Part I · Page Number
Item 1Business4
Item 1ARisk Factors7
Item 1BUnresolved Staff Comments12
Item 2Properties12
Item 3Legal Proceedings12
Item 4Mine Safety Disclosures12
Part II
Item 5Market for Registrant’s Common Equity, Related Stockholder Matters and13
Item 6Selected Financial Data15
Item 7Management’s Discussion and Analysis of Financial Condition and Results of Operations15
Item 7AQuantitative and Qualitative Disclosures About Market Risk18
Item 8Financial Statements, Auditor’s Notes and Supplemental Data18
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.